Sox2‐dependent inhibition of p21 is associated with poor prognosis of endometrial cancer. Issue 4 (19th April 2017)

• Record Type: Journal Article
• Authors: Yamawaki, Kaoru; Ishiguro, Tatsuya; Mori, Yutaro; Yoshihara, Kosuke; Suda, Kazuaki; Tamura, Ryo; Yamaguchi, Masayuki; Sekine, Masayuki; Kashima, Katsunori; Higuchi, Masaya; Fujii, Masahiro; Okamoto, Koji; Enomoto, Takayuki
• Is Part Of: Cancer science. Volume 108:Issue 4(2017)
• Page Start: 632
• Page End: 640
• Publication Date: 2017-04-19
• Subjects: Biomarker -- cell cycle -- endometrial cancer -- p21 -- sex‐determining region Y‐box 2; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.13196
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract : Sex‐determining region Y‐box 2 (SOX2) is an essential factor involved in the self‐renewal and pluripotency of embryonic stem cells and has functions in cell survival and progression in many types of cancers. Here, we found that several endometrial cancer cell lines expressed SOX2, which was required for cell growth. Additionally, SOX2 overexpression regulated the expression of cyclin‐dependent kinase inhibitor 1A ( CDKN1A ), and SOX2 specifically bound to p21 promoter DNA in endometrial cancer cell lines expressing SOX2. Expressions of SOX2 in endometrial cancer patients were significantly correlated with histological grade and poor prognosis. Moreover, low p21 together with high SOX2 expressions in advanced endometrial cancer patients were associated with the most unfavorable outcomes of patients. These results indicated that simultaneous measurement of SOX2 and p21 expression in endometrial cancer patients may be a useful biomarker for patient prognosis. Abstract : SOX2 is required for endometrial cancer cell growth. Expressions of SOX2 in endometrial cancer patients is significantly correlated with histological grade and poor prognosis. Low p21 together with high SOX2 expressions in advanced endometrial cancer patients are associated with the most unfavorable outcomes of patients.